Verici Dx plc (AIM:VRCI)

Market Cap	5.15M -45.6%
Revenue (ttm)	2.65M +84.1%
Net Income	-5.94M
EPS	-0.00
Shares Out	2.29B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,521,732
Open	0.2074
Previous Close	0.2100
Day's Range	0.1943 - 0.2500
52-Week Range	0.1943 - 0.9900
Beta	1.19
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 15, 2026

About Verici Dx

Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 18
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: VRCI

Financial Performance

In 2025, Verici Dx's revenue was $3.66 million, an increase of 9.73% compared to the previous year's $3.34 million. Losses were -$6.93 million, 18.0% more than in 2024.

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error